Cargando…
Treatment with rGDF11 does not improve the dystrophic muscle pathology of mdx mice
BACKGROUND: Duchenne muscular dystrophy (DMD) is an inherited lethal muscle wasting disease characterized by cycles of degeneration and regeneration, with no effective therapy. Growth differentiation factor 11 (GDF11), a member of the TGF-β superfamily and myostatin homologous, has been reported to...
Autores principales: | Rinaldi, Fabrizio, Zhang, Yu, Mondragon-Gonzalez, Ricardo, Harvey, Jeffrey, Perlingeiro, Rita C. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906773/ https://www.ncbi.nlm.nih.gov/pubmed/27303621 http://dx.doi.org/10.1186/s13395-016-0092-8 |
Ejemplares similares
-
A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice
por: Jin, Quan, et al.
Publicado: (2019) -
Hormonal Receptors in Skeletal Muscles of Dystrophic Mdx Mice
por: Feder, David, et al.
Publicado: (2013) -
Dysfunctional Muscle and Liver Glycogen Metabolism in mdx Dystrophic Mice
por: Stapleton, David I., et al.
Publicado: (2014) -
Dystrophic phenotype improvement in the diaphragm muscle of mdx mice by diacerhein
por: Mâncio, Rafael Dias, et al.
Publicado: (2017) -
A proteasome inhibitor fails to attenuate dystrophic pathology in mdx mice
por: Selsby, Joshua, et al.
Publicado: (2012)